The drug boceprevir helps cure hard-to-treat hepatitis C, says Saint Louis University investigator Bruce R. Bacon, M.D., author of the March 31 New England Journal of Medicine article detailing the study’s findings. The results, which were first reported at the 61st annual meeting of the American Association for the Study of Liver Disease’s last November, offer a brighter outlook for patients who have not responded to standard treatment.
A new drug may give hope to those suffering from Hepatitis C who have not responded to standard treatment.









Preparing for Shell Buckling Knockdown Factor test at the Marshall Center. (NASA/MSFC)